Abstract library

17 results for "Álvarez".
#241 One-year Response to Everolimus in a Case of Advanced Pancreatic NET
Introduction: A stage IV pancreatic NET (30 mitoses/10 PF and Ki-67 index=40%) with liver and peritoneal metastases was diagnosed in a 35-year-old woman in June 2008. Characteristics: ECOG2 and CgA 1701 ng/ml.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#257 Doxorubicin, Etoposide and Cisplatin as first-line Treatment in Advanced Adrenocortical Carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis in advanced setting due to its low chemosensibility. Mitotane and cisplatin-based regimens are the most frequently used treatments.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#460 Treatment of Unresectable Metastatic GEP NETs: Data From a Prospective Observational Unicentric Study
Introduction: In 2010 Everolimus, Sunitinib and Capecitabine plus Temozolamide confirmed efficacy in NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Paula J Fonseca
#544 Second Primary Tumor in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): Data From a Retrospective Observational Unicentric Study
Introduction: It is known that GEPNETs are associated with a high incidence of second primary tumors, especially in the context of inherited syndromes and synchronous injuries to the intestine.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Paula J Fonseca
#639 Clinical Features and Treatment of GEP NETs in a Spanish Hospital Through 8 Years
Introduction: There are discrepancies in Gastroenteropancreatic NETs (GEPNET) incidence, characteristics and patterns of care among institutional registries and countries.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Msc MD María del Pilar Solis
#641 Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) Management in a Spanish University Hospital
Introduction: GEP-NETs are malignant entities poorly understood still, deserving important attention for a better management of the disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Msc MD María Del Pilar Solis-Hernandez
#642 Correlation Between Chromogranin A and RECIST in Neuroendocrine Tumors’ Treatment
Introduction: High Chromogranin A (CGA) levels have been associated with both tumor burden and the secretory activity of GEPNETs specially carcinoids.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: PhD MD Paula Jimenez Fonseca
#882 Gene Expression Characterization of Gastroenteropancreatic Neuroendocrine Tumors [GEPNETS: Gastrointestinal and Pancreatic NETs (GINETs and pNETs)] and Their Correlation with Clinical Factors and Tumor Behavior
Introduction: GEP-NETs are a heterogenous group of tumors with different molecular backgrounds and clinical outcome.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: J A Díaz Pérez
#966 Evaluation of Lysyl Oxidase-Like-2 (LOXL2) Expression by Immunohistochemistry (IHC) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): A Retrospective Analysis and Comparison with PTEN
Introduction: A better understanding of the relationship between the stroma and the cancer cells of this group of malignancies remains a challenge. LOXL2 is an enzyme that contributes to the synthesis and stabilization of the cellular matrix and plays a role in angiogenesis.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Dr Jorge Barriuso
Keywords: LOXL2, GEP-NET
#1153 Prognostic Role of Diabetes Mellitus (DM) and Metformin (MET) Therapy in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs) Treated with Everolimus (EVE)
Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio